Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Finished Goods (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Finished Goods for 4 consecutive years, with $249.4 million as the latest value for Q4 2025.

  • Quarterly Finished Goods fell 5.65% to $249.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $249.4 million through Dec 2025, down 5.65% year-over-year, with the annual reading at $249.4 million for FY2025, 5.65% down from the prior year.
  • Finished Goods for Q4 2025 was $249.4 million at BeOne Medicines, down from $264.3 million in the prior quarter.
  • The five-year high for Finished Goods was $264.3 million in Q4 2024, with the low at $249.4 million in Q4 2025.